16 terminated. 16 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Terminated 16 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 2 | Terminated 2 |
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants mRNA-1273.214, Placebo - SARS-CoV-2 | Phase 2 | Terminated | ModernaTX, Inc. | 68 | 2022-09-30 | 2025-11-26 |
| High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients mRNA-1273 (Moderna COVID-19 vaccine) - Lung Transplant Recipient, SARS-CoV-2 | Phase 1 / Phase 2 | Terminated | University of California, Los Angeles | 19 | 2022-03-10 | 2025-03-26 |
| COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease REGN14256, imdevimab, casirivimab + imdevimab - SARS-CoV-2 | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 25 | 2021-11-08 | 2025-10-28 |
| Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 ARCT-021 - SARS-CoV-2 | Phase 2 | Terminated | Arcturus Therapeutics, Inc. | 65 | 2021-01-04 | 2024-12-30 |
| Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 PLN-74809, Placebo - Acute Respiratory Distress Syndrome, SARS-CoV-2 | Phase 2 | Terminated | Pliant Therapeutics, Inc. | 6 | 2020-10-22 | 2022-11-17 |
| Lactoferrin for Prevention of COVID-19 in Health Care Workers Bovine Lactoferrin, Maltodextrin - SARS-CoV-2 | Phase 2 | Terminated | Universidad Peruana Cayetano Heredia | 209 | 2020-10-17 | 2021-12-09 |
| Control of COVID-19 Outbreaks in Long Term Care Favipiravir, Favipiravir Placebo - COVID-19, SARS-CoV-2 | Phase 2 | Terminated | Appili Therapeutics Inc. | 67 | 2020-10-16 | 2023-02-21 |
| Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise Abatacept, Placebo - COVID-19, SARS-CoV-2 | Phase 2 | Terminated | Bristol-Myers Squibb | 61 | 2020-10-14 | 2022-10-07 |
| DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury DUR-928, Placebo - SARS-CoV-2 | Phase 2 | Terminated | Durect | 2 | 2020-09-21 | 2022-08-05 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults GX-19, Saline - SARS-CoV-2 | Phase 1 / Phase 2 | Terminated | Genexine, Inc. | 60 | 2020-06-17 | 2025-08-20 |
| Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) Hydroxychloroquine - COVID19, Hydroxychloroquine | Phase 2 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 155 | 2020-05-14 | 2025-03-10 |
| Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection Standard of care, Hydroxychloroquine, Azithromycin - SARS-CoV-2 | Phase 2 | Terminated | Duke University | 11 | 2020-04-17 | 2021-05-17 |
| Treatment for COVID-19 in High-Risk Adult Outpatients Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Terminated | University of Washington | 289 | 2020-04-16 | 2022-08-08 |
| Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. Emapalumab, Anakinra - SARS-CoV-2 | Phase 2 / Phase 3 | Terminated | Swedish Orphan Biovitrum | 16 | 2020-04-02 | 2022-03-10 |
| Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 Hydroxychloroquine Sulfate + Azithromycin, Hydroxychloroquine Sulfate - SARS-CoV-2, COVID-19 | Phase 2 | Terminated | Rutgers, The State University of New Jersey | 75 | 2020-04-01 | 2023-02-28 |
COVID-19 (10) · Coronavirus Infections (4) · Respiratory Distress Syndrome (2) · Cardiovascular Diseases (1) · Cytokine Release Syndrome (1) · Dyspnea (1) · Heart Failure (1) · Myocardial Infarction (1) · Pneumonia (1) · Pulmonary Edema (1) · Respiratory Insufficiency (1) · Virus Diseases (1)
Lung Diseases (11) · Respiratory Tract Diseases (11) · Coronaviridae Infections (10) · Infections (10) · Nidovirales Infections (10) · Pneumonia, Viral (10) · RNA Virus Infections (10) · Respiratory Tract Infections (10) · Pneumonia (9) · Virus Diseases (9) · Coronavirus Infections (6) · Respiration Disorders (2) · Heart Diseases (1) · Infarction (1) · Inflammation (1)
Hydroxychloroquine (4) · Azithromycin (3) · 2019-nCoV Vaccine mRNA-1273 (1) · Abatacept (1) · Ascorbic Acid (1) · Emapalumab (1) · Folic Acid (1) · Interleukin 1 Receptor Antagonist Protein (1) · Lactoferrin (1) · Lopinavir (1) · REGN14256 (1) · Ritonavir (1) · Saline Solution (1) · Sodium Chloride (1) · Standard of Care (1)
Appili Therapeutics Inc. (1) · Arcturus Therapeutics, Inc. (1) · Bristol-Myers Squibb (1) · Duke University (1) · Durect (1) · Genexine, Inc. (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · ModernaTX, Inc. (1) · PhaseBio Pharmaceuticals Inc. (1) · Pliant Therapeutics, Inc. (1) · Regeneron Pharmaceuticals (1) · Rutgers, The State University of New Jersey (1) · Swedish Orphan Biovitrum (1) · Universidad Peruana Cayetano Heredia (1) · University of California, Los Angeles (1)
United States (11) · Italy (2) · Canada (1) · Peru (1) · Puerto Rico (1) · Singapore (1) · South Korea (1)
Allison J McGeer, MD (1) · Christine Johnston, MD, MPH (1) · Emanuele Nicastri, MD (1) · Giovanni Martinelli, Prof. (1) · Jason Stout, MD (1) · JungWon Woo, Ph.D. (1) · Pierluigi Viale, Prof. (1) · Robert Gordon, MD (1) · Sabiha Hussain, MD (1) · Steven K. Libutti, MD, FACS (1) · Theresa J Ochoa, MD, PhD (1) · Yusaku Michael Shino, MD (1)
PMID 32736597, PMID 33681731, PMID 33935163, PMID 34473343, PMID 35604806, PMID 36474100